BSF Enterprise (LSE:BSFA), the biotechnology company focused on tissue engineering, lab-grown materials and bioactive solutions, said Indigo Capital Investments has exercised a notice to convert £100,283 of the £1 million outstanding under the company's convertible loan note instrument.
The conversion will result in BSF issuing 10 million new shares of 1 penny each to Indigo, ranking equally with existing shares.
Following the share issue, BSF's total issued share capital and voting rights will stand at 203.75 million shares.
The move trims part of the debt owed under the loan note facility, though the bulk of the £1 million instrument remains outstanding.
News Intelligence what this means for the company
Indigo Capital Investments has converted £100,283 of its £1 million convertible loan note into 10 million new BSF Enterprise shares, reducing the company's outstanding debt by roughly 10%. The conversion is modest in scale relative to the loan facility—£900,717 remains outstanding—and BSF's share count rises to 203.75 million shares, diluting existing holders but preserving the company's cash position.
The conversion chips away at debt without requiring cash outlay, but the bulk of the £1 million facility persists as a liability. For a biotech dependent on licensing revenue from ETSYL and T-Rex Leather partnerships, this partial debt-to-equity swap is a minor refinancing event that does not materially alter the capital structure or near-term funding outlook.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
